A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia : Episode 10

Progression on Frontline Ibrutinib in CLL

Dec 24, 2019

Transcript:

Related Videos

Related Content

Demystifying the Role of Palliative Care in the Oncology Clinic

January 27th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

January 19th 2023

Demystifying the Role of Palliative Care in the Oncology Clinic

January 27th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

January 19th 2023

Demystifying the Role of Palliative Care in the Oncology Clinic

January 27th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

January 19th 2023

Related Content

Demystifying the Role of Palliative Care in the Oncology Clinic

January 27th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

January 19th 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.